Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016-Reference-Cited by-同舟云学术

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016

Published:2021-03 Issue:2 Volume:3 Page:173-182.e1
ISSN:2590-0595
Container-title:Kidney Medicine
language:en
Short-container-title:Kidney Medicine

Author:

Zhao Julie Z.,Weinhandl Eric D.,Carlson Angeline M.,St. Peter Wendy L.

Publisher

Elsevier BV

Subject

Nephrology,Internal Medicine

Reference35 articles.

1. Microvascular and macrovascular complications of diabetes;Fowler;Clin Diabetes,2008

2. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States. Advanced stage CKD (stages 3 and 4) Prevalence by year and diabetes status in U.S. adults. Accessed February 14, 2020. https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q702#refreshPosition

3. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. Accessed February 14, 2020. https://care.diabetesjournals.org/content/41/Supplement_1/S73

4. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency;Arjona Ferreira;Diabetes Care,2013

5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes;Journal of Clinical Medicine;2024-02-28

2. A Novel Chronic Kidney Disease Phenotyping Algorithm Using Combined Electronic Health Record and Claims Data;Clinical Epidemiology;2023-03

3. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States;Kidney Medicine;2023-01

4. The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review;Cureus;2022-12-07

5. Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States;Kidney Medicine;2022-08